TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy.

The longitudinal profiles of secondary outcomes including HOMA-IR, QUICKI, and revised QUICKI at weeks 12, 24, and 48 for arm D compared with the control arm did not show any significant difference in HOMA-IR; however, the treatment effect of arm D compared with arm A for the longitudinal revised QUICKI was marginally significant (0.004; 95% CI, 0.000–0.008; P = .05), suggesting that telmisartan (80 mg) led to a small reduction in insulin resistance over a period of 48 weeks (see Supplementary data for all summary statistics).

also in 26,082 other papers